Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

ArQule, Inc. to Present at Seventh Annual Needham & Company Biotechnology and Medical Technology Conference.


WOBURN, Mass. -- ArQule, Inc. (Nasdaq: ARQL) today announced that it will present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference on Thursday, June 12, 2008 at 2:00 p.m. eastern time.

ArQule's presentation will be web cast live and can be accessed through the investor relations section of the Company's website, www.arqule.com. The conference will be held at the New York Palace
  • Palace Theatre, New York
  • New York Palace, Budapest, Hungary
 Hotel, New York.

About ArQule

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead products, which are in clinical-stage development, consist of ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase Receptor tyrosine kinases (RTK)s are the high affinity cell surface receptors for many polypeptide growth factors, cytokines and hormones. Of the ninety unique tyrosine kinase genes idenitified in the human genome, 58 encode receptor tyrosine kinase proteins. , and ARQ 501, an activator of the cell's DNA DNA: see nucleic acid.
DNA
 or deoxyribonucleic acid

One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes.
 damage response mechanism mediated by the E2F-1 transcription factor. The Company's most advanced pre-clinical development programs are focused on ARQ 761, a second-generation E2F-1 product candidate, as well as compounds that inhibit the Eg5 kinesin spindle protein and the BRAF kinase. ArQule's discovery efforts are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP ATP: see adenosine triphosphate.
ATP
 in full adenosine triphosphate

Organic compound, substrate in many enzyme-catalyzed reactions (see catalysis) in the cells of animals, plants, and microorganisms.
 (adenosine triphosphate triphosphate /tri·phos·phate/ (tri-fos´fat) a salt containing three phosphate radicals.

tri·phos·phate
n.
A salt or ester containing three phosphate groups.
), an energy source for cells.
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Conference news
Date:Jun 5, 2008
Words:207
Previous Article:Open Solutions' Member-Centric Relationship-based Core Processing Platform Gains Momentum.
Next Article:3D Systems to Showcase Four Technologies at Japan's Largest Manufacturing Exhibition.
Topics:



Related Articles
ArQule executes four year collaboration with R.W. Johnson Pharmaceutical Research Institute for the discovery of novel pharmaceuticals.
ARQULE/KYOWA HAKKO KOGYO SIGN ARQ 197 ASIA LICENSE.
Needham & Company, LLC's Sixth Annual Biotechnology & Medical Technology Conference New York Palace Hotel June 13-14, 2007.
Analogic President & CEO to Present at Sixth Annual Needham & Company Biotechnology and Medical Technology Conference.
Ligand to Present at the Needham & Company Biotechnology and Medical Technology Conference on June 11.
ZIOPHARM Oncology to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference.
Targacept to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference.
The Medicines Company to Participate in the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference.
Analogic President & CEO to Present at Seventh Annual Needham & Company Biotechnology & Medical Technology Conference.
Needham & Company, LLC To Host Seventh Annual Biotechnology & Medical Technology Conference on June 11-12.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles